Epic Sciences’ Dena Marrinucci, PhD, Recognized for Her Outstanding Achievements in Entrepreneurial and Technical Innovation

It has been a month of well-deserved recognition for co-founder and CSO of Epic Sciences, Dena Marrinucci, PhD, as she was recently named in the 2015 list of 100 outstanding professionals in the life-sciences industry by PharmaVOICE and today was named one of the Top Innovators Under 35 by MIT Technology Review.

Dr. Marrinucci became a pioneer in the circulating tumor cell (CTC) field while earning her Ph.D. from The Scripps Research Institute (TSRI) where her thesis work became the basis for Epic Sciences.  Since receiving her Ph.D., Dr. Marrinucci has taken a senior management position at Epic leading the Companion Diagnostic (CDx) Group, oversees all diagnostic partnering collaborations and leads multiple internal research projects as well as Clinical Operations.  As study director, she is extensively involved in all on-going clinical trials from initiation of the study, to execution of experiments, to data analysis and interpretation.

Every year, PharmaVOICE and MIT Technology Review receive thousands of nominations from readers for the most influential corporate and technical leaders, in their field. After evaluating all candidates and narrowing the list to the top few, Dr. Marrinucci was chosen because of her groundbreaking work in developing and advancing a new technology to unlock the promise of using a simple blood test, called a liquid biopsy, to manage cancer treatments.  

Epic Sciences is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of cellular, genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs).  Epic’s no cell left behind™ technology helps will help match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. 

Domain Associates has seen the promise in Epic Sciences from the early stages of development and has been increasingly proud of the direction and success the company has had in implementing its technology and improving cancer diagnostics.  Ultimately, Domain’s goal is focused on finding the best ways to deliver the best care and create great diagnostic companies that not only help patients but also provide substantial and sustainable value to the healthcare system.  Epic Sciences is fulfilling that goal by improving liquid biopsy tests that offer more accurate and precise therapy selection and early drug resistance detection.  Read more here on Domain’s strategy for investing in companies with enabling technologies that can unlock areas important for diagnostics.

Visit www.epicsciences.com to learn more about Dena’s accomplishments and Epic’s innovative technology.